Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2531 • 2019 ACR/ARP Annual Meeting
Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In the general population, low vitamin D has been associated with adverse pregnancy outcomes including preterm birth, pre-eclampsia and small for gestational age. In…
Abstract Number: 2565 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Richard Dimelow ¹, Beulah Ji² and Herbert Struemper ³, ¹GSK, Stevenage, United Kingdom, ²GSK, Uxbridge, Middlesex, United Kingdom, ³GSK, Research Triangle Park
Background/Purpose: Belimumab is approved in adults with active SLE and for childhood-onset SLE (cSLE). PLUTO, a Phase 2, placebo-controlled, double-blind trial (114055; NCT01649765), was the first…
Abstract Number: 2813 • 2019 ACR/ARP Annual Meeting
Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis
Cecilia Svanberg ¹, Helena Enocsson ¹, Klara Martinsson ¹, Lawrence Potempa ², Ibraheem Rajab ², Jonas Wetterö ¹, Marie Larsson ¹ and Christopher Sjöwall³, ¹Linköping University, Linköping, Sweden, ²Roosevelt University, Chicago, IL, ³Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune systemic disease affecting multiple organs and which is characterized by autoantibodies directed against nuclear constituents. Common autoantibody…
Abstract Number: 83 • 2019 ACR/ARP Annual Meeting
Dysfunction of TRIM21 Promotes Aberrant Plasmablast Differentiation in Systemic Lupus Erythematosus Due to the Reduction of TRIM21-mediated Ubiquitylation of IRF5
Yosuke Kunishita¹, Ryusuke Yoshimi ¹, Reikou Kamiyama ¹, Daiga Kishimoto ¹, Koji Yoshida ¹, Eijin Hashimoto ¹, Yumiko Sugiyama ², Takaaki Komiya ¹, Natsuki Sakurai ¹, Yohei Kirino ³ and Hideaki Nakajima ³, ¹Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatic Diseases / Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: TRIM21 is a member of the tripartite motif family proteins and is one of the autoantigens which react with anti-SS-A antibody (Ab) present in…
Abstract Number: 659 • 2019 ACR/ARP Annual Meeting
Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity
Sabine Zenz¹, Barbara Dreo ¹, Angelika Lackner ¹, Barbara Prietl ², Selina Kofler ², Harald Sourij ², Florentine Moazedi-Fuerst ¹, Monica D'Orazio ¹, Martin Stradner ¹, Winfried Graninger ¹ and Hans-Peter Brezinschek ¹, ¹Department of Internal Medicine/Division of Rheumatology and Immunology, Graz, Austria, ²2CBmed GmbH – Center for Biomarker Research in Medicine, Graz, Austria
Background/Purpose: B-cells play a pivotal role in the initiation and perpetuation of systemic lupus erythematosus (SLE). Recently, it has been demonstrated that in active SLE…
Abstract Number: 862 • 2019 ACR/ARP Annual Meeting
First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study
Viktoria Hermann¹, Anastas Batalov ², Svetlana Smakotina ³ and Peter Cornelisse ¹, ¹Idorsia, Allschwil, Switzerland, ²Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ³Kemerovo Regional Clinical Hospital, Kemerovo, Russia
Background/Purpose: Aberrantly activated T- and B-lymphocytes play a major pathophysiological role in SLE. Cenerimod, a potent, selective sphingosine-1-phosphate 1 receptor modulator, blocks the egress of…
Abstract Number: 1035 • 2019 ACR/ARP Annual Meeting
Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus
Mara Lennard Richard¹, Melissa Cunningham ², Betty Tsao ³ and Gary Gilkeson ⁴, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, ⁴Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects females (9:1) over males. Despite significant research effort, the exact mechanisms behind this compelling sex bias are undefined.…
Abstract Number: 1395 • 2019 ACR/ARP Annual Meeting
Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab
Alice Combier¹, Gaetane Nocturne ², Julien Henry ³, Rakiba Belkhir ¹, Stephan Pavy ⁴, Clotilde Le Tiec ⁵, Elise Descamps ⁴, Raphaele Seror ⁶ and Xavier Mariette ⁷, ¹Rheumatology Departement - Bicêtre Hospital, Paris, France, ²Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ³Rheumatology Departement - Bicêtre Hospital, Paris, ⁴Rheumatology Departement - Bicètre Hospital, Paris, France, ⁵Pharmacy Departement - Bicètre Hospital, Paris, France, ⁶Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France, ⁷Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: The most widely used B cell targeted therapies in auto-immune diseases (AID) is Rituximab (RTX), a murine chimeric monoclonal antibody. Among RTX’s side effects,…
Abstract Number: 1592 • 2019 ACR/ARP Annual Meeting
Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype
Marisa Mizus¹, Jessica Li ¹, Daniel Goldman ² and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in SLE patients. Hypocomplementemia, antiphospholipid antibodies, and elevated antibodies to RNP and Ro are…
Abstract Number: 1627 • 2019 ACR/ARP Annual Meeting
Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure
Chien-Chih Lai¹, Yi-Syuan Sun ¹ and Chang-Youh Tsai ², ¹Division of Allergy, Immunology, Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), ²Division of Allergy, Immunology & Rheumatology/Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: To evaluate the pathogens from bronchoalveolar lavage fluid (BALF) and risk factors of mortality in SLE patients with pneumonia and respiratory failure.Methods: Twenty-four SLE…
Abstract Number: 1936 • 2019 ACR/ARP Annual Meeting
The Expression of the Interferon Inducible Gene SERPING1 Is Reduced by Rituximab and Correlates with Clinical Response in Systemic Lupus Erythematosus
Liliana Santos Ribeiro¹, Mariea Parvaz ², Su-Ann Yeoh ² and Michael Ehrenstein ², ¹University College London, London, United Kingdom, ²University College London, London, England, United Kingdom
Background/Purpose: Abnormalities in B cells and the interferon alpha (IFN) pathway have been separately implicated in the pathogenesis of systemic lupus erythematosus (SLE). B cell…
Abstract Number: 2251 • 2019 ACR/ARP Annual Meeting
Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study
Siobhan Case¹, Corine Sinnette ², Courtnie Phillip ², Claire Grosgogeat ³, Karen Costenbader ², Cianna Leatherwood ⁴, Candace Feldman ² and Mary Beth Son ³, ¹Brigham and Women's Hospital and Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Kaiser Permanente, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) poses complex diagnostic and management challenges, which may differ depending on whether SLE was diagnosed in childhood (cSLE) or in…
Abstract Number: 2532 • 2019 ACR/ARP Annual Meeting
Effect of Treatment on Antiphospholipid Antibodies in SLE
Michelle Petri¹, Laurence Magder ² and Daniel Goldman ³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Unlike primary antiphospholipid syndrome patients, most SLE patients with antiphospholipid antibodies are on one or more treatments for their SLE that might affect levels…
Abstract Number: 2566 • 2019 ACR/ARP Annual Meeting
Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE
Dale Seguin¹, Christine Peschken ², Casandra Dolovich ¹, Ruby Grymonpre ¹, Phil St. John ¹ and Annaliese Tisseverasinghe ¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, Canada
Background/Purpose: Polypharmacy, typically defined as ≥ 5 medications (meds), is a strong risk factor for adverse clinical outcomes, including delirium, falls, hospitalization, and death, especially…
Abstract Number: 2814 • 2019 ACR/ARP Annual Meeting
Methionine Commits Immunometabolism and Epigenetic Regulation of BACH2 Loci in B Cells, Resulting in Biases Toward Plasmablast Differentiation in the Pathogenesis of SLE
Mingzeng Zhang¹, Shigeru Iwata ¹, Maiko Hajime ¹, Naoaki Ohkubo ¹, Yasuyuki Todoroki ², Hiroko Miyata ², Jie Fan ², Shingo Nakayamada ¹, Kaoru Yamagata ¹ and Yoshiya Tanaka ³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational & Environmental Health Kitakyushu, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health Japan, Kitakyushu, Japan
Background/Purpose: Amino acids play an important role in various metabolic processes. However, the role of amino acid metabolism in the regulation of human B cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].